CNR Institutional Research Information System

PINNA, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 837
AS - Asia 255
EU - Europa 60
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 1.156
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 837
SG - Singapore 242
IT - Italia 31
FI - Finlandia 19
CN - Cina 6
HK - Hong Kong 3
AE - Emirati Arabi Uniti 2
NL - Olanda 2
SE - Svezia 2
AR - Argentina 1
AT - Austria 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EE - Estonia 1
JP - Giappone 1
KE - Kenya 1
KR - Corea 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.156
Salva come PNG Salva come JPEG
Città #
Santa Clara 756
Singapore 141
Cagliari 19
Helsinki 19
Los Angeles 8
Rome 7
Phoenix 5
Hong Kong 3
Milan 2
Amsterdam 1
Ashburn 1
Auckland 1
Bratislava 1
Buenos Aires 1
Dubai 1
Forest City 1
Minsk 1
Monza 1
Nairobi 1
Prague 1
Seattle 1
Seoul 1
Stockholm 1
Tallinn 1
Tokyo 1
Vienna 1
Vimodrone 1
Warsaw 1
Totale 979
Salva come PNG Salva come JPEG
Nome #
Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease 31
Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson's disease 23
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist 22
Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems 19
Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease 19
Involvement of the protein ras homolog enriched in the striatum, rhes, in dopaminergic neurons' degeneration: Link to parkinson's disease 17
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease 16
Genes implicated in familial parkinson's disease provide a dual picture of nigral dopaminergic neurodegeneration with mitochondria taking center stage 15
Neurofarmacologia nel trattamento della Malattia di Parkinson e nuovi approcci farmacologici 15
Fos expression induced by olanzapine and risperidone in the central extended amygdala 15
Influence of Age and Genetic Background on Ethanol Intake and Behavioral Response Following Ethanol Consumption and During Abstinence in a Model of Alcohol Abuse 15
Lack of rhes increases mdma-induced neuroinflammation and dopamine neuron degeneration: Role of gender and age 14
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 14
Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia 14
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 13
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A(2A) receptor antagonist 13
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of parkinson's disease 13
Neurobiology of Parkinson's Disease 13
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 12
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 12
Farmaci Antiparkinsoniani ed Attivi in altri disturbi motori 12
Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease 11
INDUCTION OF FOS-LIKE IMMUNOREACTIVITY IN THE CENTRAL EXTENDED AMYGDALA BY ANTIDEPRESSANT DRUGS 11
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 11
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 10
ADENOSINE A2A ANTAGONISTS AND PARKINSON S DISEASE: NEW FINDINGS ON PARKINSONIAN TREMOR 10
C-FOS EXPRESSION AS A MOLECULAR MARKER IN CORTICOTROPIN-RELEASING FACTOR-INDUCED SEIZURES 10
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease article 10
RECEPTOR ANTAGONISTS IMPROVE AKINESIA AND SENSORY-MOTOR DEFICITS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON S DISEASE 10
Behavioural characterization of engrailed mutant mice as model of Parkinson's disease 10
PRIMING OF 6-HYDROXYDOPAMINE-LESIONED RATS WITH L-DOPA OR QUINPIROLE RESULTS IN AN INCREASE IN DOPAMINE D1 RECEPTOR-DEPENDENT CYCLIC AMP PRODUCTION IN STRIATAL TISSUE 10
ADENOSINE A2A RECEPTOR AGONISTS INCREASE FOS-LIKE IMMUNOREACTIVITY IN MESOLIMBIC AREAS 10
Decreased striatal adenosine extracellular levels and increased A2A receptors mRNA after dopamine denarvation 10
Symptomatic efficacy of mucuna pruriens seed extract in rodent model of Parkinson s disease 10
Role of adenosine A(2A) receptors in motor control: relevance to Parkinson's disease and dyskinesia 10
EVALUATION OF LOW AND HIGH DYSKINETIC POTENTIAL OF DOPAMINE AGONIST DRUGS IN THE RAT 6-OHDA MODEL OF PARKINSON S DISEASE 10
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D1 but not D2 receptor agonists 10
INTERACTION BETWEEN DOPAMINE AND ADENOSINE A2A RECEPTORS AS A BASIS FOR THE TREATMENT OF PARKINSON'S DISEASE 10
A novel therapeutic strategy for the prevention of the onset of dyskinesia in the therapy of Parkinson's disease 10
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists 10
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 10
Sensitisation in turning behaviour and abnormal involuntary movements in 6-hydroxydopamine lesioned rats: Influence of the environment in which tests are performed 10
Behavioral, Neurochemical, and Electrophysiological Changes in an Early Spontaneous Mouse Model of Nigrostriatal Degeneration 10
A novel therapeutic strategy to prevent the onset of dyskinesia in models of Parkinson's disease: acute and chronic studies. 10
MODULATION BY ADENOSINE A2A RECEPTORS OF DOPAMINE-MEDIATED MOTOR BEHAVIOR AS A BASIS FOR ANTIPARKINSON'S DISEASE DRUGS 10
M. Morelli, N. Simola, A. Pinna, S. Pontis 10
ADENOSINE A2A RECEPTOR ANTAGONISTS IN THE THERAPY OF PARKINSON'S DISEASE 10
DIFFERENTIAL INDUCTION OF FOS-LIKE-IMMUNOREACTIVITY IN THE EXTENDED AMYGDALA AFTER HALOPERIDOL AND CLOZAPINE 9
. Interaction between metabotropic adenosina A2A and glutamate MGLU5 receptors in parkinsonian-like muscle rigidity and tremor 9
BEHAVIOURAL CHARACTERIZATION OF ENGRAILED MUTANT MICE AS MODEL OF PARKINSON S DISEASE. 9
Sensitizzazione alla caffeina e sensitizzazione crociata all'amfetamina in ratti lesi con 6-idrossidopamina: studio comportamentale e biochimico 9
Adenosine A(2A) receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. 9
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 9
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 9
MDMA ADMINISTRATION DURING ADOLESCENCE EXACERBATES MPTP-INDUCED COGNITIVE IMPAIRMENT, NEURODEGENERATION AND NEUROINFLAMMATION IN MOTOR, LIMBIC AND CORTICAL AREAS 9
Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry 9
DOPAMINE AND ADENOSINE RECEPTOR INTERACTION AS BASIS FOR A TREATMENT OF PARKINSON S DISEASE 9
ATTENUATION OF MPTP-INDUCED NEURODEGENERATION BY NCX 2216, A NITRIC OXIDE-RELEASING DERIVATIVE OF FLURBIPROFEN 9
Model of dyskinesia in 6-hydroxydopamine-lesioned rats: validity of sensitization in turning behaviour and abnormal involuntary movements. 9
Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions 9
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 9
SENSITIZATION TO TURNING BEHAVIOUR AND ABNORMAL INVOLUNTARY MOVEMENTS IN 6-HYDROXYDOPAMINE LESIONED RATS AS MODELS OF DYSKINESIA. 9
Symptomatic and neuroprotective effects of A2A receptor antagonists in Parkinson's disease 9
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 9
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 9
Adenosine A(2A) receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats 9
MOTOR STIMULANT EFFECTS OF THE ADENOSINE A2A RECEPTOR ANTAGONIST SCH 58261 DO NOT DEVELOP TOLERANCE AFTER REPEATED TREATMENTS IN 6-HYDROXYDOPAMINE-LESIONED RATS 9
Caffeine consumption and Changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine. Published in Advances in psychology research 9
BLOCKADE OF A2a ADENOSINE RECEPTORS POSITIVELY MODULATES TURNING BEHAVIOUR AND c-FOS EXPRESSION INDUCED BY D1 AGONISTS IN DOPAMINE-DENERVATED RATS 9
Therapeutic potential and antidyskinetic activity of the combined antagonism of adenosine A2A receptors and stimulation of 5HT1A/1B receptors in models of Parkinson's disease: acute and chronic studies. 9
INVOLVEMENT OF ADENOSINE A2A RECEPTORS IN THE INDUCTION OF C-FOS EXPRESSION BY CLOZAPINE AND HALOPERIDOL 9
Behavioural Correlates of Dopaminergic Agonists' Dyskinetic Potential in the 6-OHDA-Lesioned Rat 9
A2A receptor antagonists improve akinesia and sensory-motor deficits in the 6-hydroxydopamine model of Parkinson's disease 9
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. 9
MODULATORY ROLE OF ADENOSINE A2A RECEPTORS AS BASIS FOR THE USE OF A2A ANTAGONISTS IN THE TREATMENT OF PARKINSON S DISEASE 9
Pharmacological Therapy of Parkinson's Disease: Current Options and New Avenuew 9
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioural and biochemical characterization as an antiparkinsonian drug 9
L-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors 9
SUBCHRONIC-INTERMITTENT CAFFEINE AMPLIFIES THE MOTOR EFFECTS OF AMPHETAMINE IN RATS 8
A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A(2A) Receptor Antagonists 8
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 8
'Priming' to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message 8
ADENOSINE A2A RECEPTOR ANTAGONIST TREATMENT OF PARKINSON S DISEASE. In The basal ganglia pathophysiology: recent advances 8
ENGRAILED MUTANT MICE AS MODEL OF PARKINSON S DISEASE: BEHAVIOURAL CHARACTERIZATION. LIMPE 8
Cross-sensitization between caffeine and amphetamine but not cocaine-induced locomotor behavior 8
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 8
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats 8
Different patterns of behavior and gene expression induced by chronic L-dopa and A(2A) antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 8
Behavioral and biochemical characterization as antiparkinsonian drug of the new adenosine A2A antagonist 8-ethoxy-9-ethyladenine 8
ALTERED RESPONSE OF STRIATAL AND PALLIDAL NEURONS AND UNBALANCED MODULATION OF SUBSTANTIA NIGRA RETICULATA ACTIVITY MAY UNDERLIE ABNORMAL MOVEMENTS IN SUBCHRONICALLY L-DOPA TREATED RATS. 8
SENSITIZATION TO TURNING BEHAVIOUR AND ABNORMAL INVOLUNTARY MOVEMENTS IN 6-HYDROXYDOPAMINE LESIONED RATS: INHFLUENCE OF THE ENVIRONMENT IN WHICH TESTS ARE PERFORMED 8
Combined microdialysis and Fos immunohistochemistry for the estimation of dopamine neurotransmission in the rat caudate-putamen 8
New adenosine A2A receptor antagonists: actions on Parkinson's disease models 8
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. 8
Neuroadaptive changes in striatum and substantia nigra reticulata associated with a dyskinetic L-DOPA treatment are not induced by the low dyskinetic drug ropinirole 8
ADENOSINE A(2) RECEPTORS STIMULATE C-FOS EXPRESSION IN STRIATAL NEURONS OF 6-HYDROXYDOPAMINE-LESIONED RATS 8
Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease 8
Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2- mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression 8
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 8
Blockade of NMDA receptors differentially affects D-1 and D-2 mediated turning behavior in the 6-hydroxydopamine model of Parkinson 8
Totale 1.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.234
article - articoli 3.137
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 517
Totale 8.888
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20244 0 0 0 0 0 0 0 0 2 0 1 1
2024/20251.211 6 11 162 85 674 134 40 66 33 0 0 0
Totale 1.215